Actinogen Medical Ltd

Australian biotechnology company Actinogen Medical (ASX: ACW) has received further positive analysis from studies of its Xanamem treatment for symptoms of depression. The consistent benefits observed in the XanaCIDD phase 2a depression trial data support the conclusion that a 10 milligram Xanamem dose is clinically active in controlling brain cortisol and has clinically-significant anti-depressant activity. […]

Inflation was the word on everybody’s lips as they dumped shares on the last trading day of the financial year but it was the price of goods and services rather than shares that had caught their attention. The week’s stunning news that inflation had reared back up to 4% for the year to May brought […]

A biomarker trial of Actinogen Medical’s (ASX: ACW) lead candidate Xanamem has been published in the peer-reviewed Journal of Alzheimer’s Disease, with results showing the drug has the potential to slow disease progression in patients with elevated levels of phosphorylated tau (pTau). The trial comprised 72 participants from Actinogen’s previous XanADu Phase 2a trial who […]

Actinogen Medical (ASX: ACW) has treated the first subject in its clinical trial of patients with biomarker-positive mild to moderate Alzheimer’s disease. The XanaMIA Phase 2b trial involves 220 participants with elevated levels of the blood biomarker pTau and measures the effects of a Xanamem 10mg daily dose versus placebo over a 36-week treatment period. […]